Comparative Pharmacology
Head-to-head clinical analysis: ARIDOL versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIDOL versus PYLORI CHEK BREATH TEST.
ARIDOL vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aridol (mannitol) is an osmotic agent that, when inhaled, increases airway osmolarity, leading to release of mediators from mast cells and eosinophils, causing bronchoconstriction in susceptible individuals. It is used as a bronchial challenge test to assess airway hyperresponsiveness.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
For bronchial challenge testing: inhaled dose of 5 mg (one vial) via nebulizer, single administration.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
16.1 ± 8.5 minutes in healthy adults. Clinical context: Short half-life allows repeated provocative testing within 2–3 hours.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Primarily renal excretion of unchanged mannitol. Approximately 80% of the administered dose is excreted unchanged in urine within 12 hours; minor biliary/fecal elimination (<5%).
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent